Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Increasing lines of evidence indicate that the biologically active form of vitamin D, calcitriol (1,25-dihydroxyvitamin D3), prevents cancer progression by reducing cell proliferation, increasing cell differentiation, and inhibiting angiogenesis, among other potential roles. Cancer cells in solid tumors preferably undergo the “Warburg effect” to support cell growth by upregulating glycolysis, and the glycolytic intermediates further serve as building blocks to generate biomass. The objective of the current study is to investigate whether calcitriol affects glucose metabolism and cell growth in human colorectal cancer cells. Calcitriol reduced the expression of cyclin D1 and c-Myc. In addition, calcitriol reduced the expression of glucose transporter 1 (GLUT1) and key glycolytic enzymes and decreased extracellular acidification rate but increased oxygen consumption rate in human colorectal cancer cells. In a subcutaneous HT29 xenograft NOD/SCID mouse model, the volume and weight of the tumors were smaller in the calcitriol groups as compared with the control group, and the expression levels of GLUT1 and glycolytic enzymes, hexokinase 2 and lactate dehydrogenase A, were also lower in the calcitriol groups in a dose-responsive manner. Our data indicate that calcitriol suppresses glycolysis and cell growth in human colorectal cancer cells, suggesting an inhibitory role of the biologically active form of vitamin D in colorectal cancer progression.

Details

Title
Calcitriol Suppresses Warburg Effect and Cell Growth in Human Colorectal Cancer Cells
Author
Chun-Yin, Huang 1 ; Yu-Ting, Weng 2 ; Po-Chen, Li 1 ; Hsieh, Nien-Tsu 1 ; Li, Chun-I 3 ; Hsiao-Sheng, Liu 4 ; Lee, Ming-Fen 2   VIAFID ORCID Logo 

 Department of Nutrition, China Medical University, Taichung 406040, Taiwan; [email protected] (C.-Y.H.); [email protected] (Y.-T.W.); [email protected] (P.-C.L.); [email protected] (N.-T.H.) 
 Department of Nutrition, China Medical University, Taichung 406040, Taiwan; [email protected] (C.-Y.H.); [email protected] (Y.-T.W.); [email protected] (P.-C.L.); [email protected] (N.-T.H.); Department of Nutrition and Health Sciences, Chang Jung Christian University, Tainan 711301, Taiwan 
 Department of Microbiology and Immunology, National Cheng Kung University, Tainan 70101, Taiwan; [email protected] (C.-I.L.); [email protected] (H.-S.L.) 
 Department of Microbiology and Immunology, National Cheng Kung University, Tainan 70101, Taiwan; [email protected] (C.-I.L.); [email protected] (H.-S.L.); Center for Cancer Research, Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan 
First page
963
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20751729
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2576445500
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.